AstraZeneca PLC (NASDAQ:AZN)’s Q4 2024 financial results highlight robust growth despite some challenges. Total revenue for ...

It is one of the best UK stocks to buy. Overall, 55 hedge funds were bullish on AstraZeneca PLC (NASDAQ:AZN) in Q4 2024, and it was part of 14 billionaire portfolios that had combined stakes worth ...

AstraZeneca PLC (NASDAQ:AZN – Free Report) – Zacks Research cut their Q4 2026 EPS estimates for AstraZeneca in a research report issued on Wednesday, April 9th. Zacks Research analyst R.

Discover how Cellectis SA (CLLS) is advancing its CAR T therapies and securing financial stability through strategic partnerships and investments.

Soliris is used to treat rare blood disorders. AstraZeneca earned more than $1.4 billion from sales of the drug in the first half of 2024, according to a company report. EmblemHealth said in the ...